Companies › Palisade Bio
1 active drug program in 2 registered trials: 1 Phase 2, 1 Phase 1; Immunology; next expected readout Oct 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| PALI-2108 phosphodiesterase-4 (PDE4) inhibitor | PDE4 | Phase 2 | Ulcerative Colitis (UC); Fibrostenotic Crohn's Disease | Oct 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07428096 | PALI-2108 | Phase 1 | Fibrostenotic Crohn's Disease | Immunology | Jan 2026 |
| NCT07845487 | PALI-2108 | Phase 2 | Ulcerative Colitis (UC) | Immunology | Oct 2027 |
Cash of $125m on 2026-06-30; operating cash outflow about $23m a year; runway about 64 months at that burn, to Nov 2031; 1 of 1 coming phase 2-3 readouts fall inside that runway
Press releases filed as 8-K in the last year:
Held by 11 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.
Integrative Skin Science and Research Ganzhou Hemay Pharmaceutical Aclaris Therapeutics Oruka Therapeutics Arcutis Biotherapeutics
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.